8-week mouse screen tests five longevity candidates for benefits and early toxicity
In an 8-week mouse study, five candidate anti-aging treatments produced compound-specific effects on weight, strength, temperature, activity, cognition and blood or urine measures; rapamycin + Smer28 was linked to anemia in 2 of 5 mice. [1]
Automatic summary · not editorially reviewed
The key findings
Over 8 weeks, mice received one of five candidate anti-aging treatments, and body weight, temperature, food intake, grip strength, activity, cognition, social behavior and blood and urine measures were assessed. [1]
Rapamycin + Smer28 modestly improved strength and sociability but induced anemia in 2 of 5 mice, indicating potential dose-dependent toxicity. [1]
The authors describe the approach as enabling prioritization and dose refinement before full lifespan studies, and say it is, to their knowledge, the first comprehensive preclinical mouse aging study fully funded through tokenized decentralized science. [1]
The source at a glance
- Study type / format
- Preclinical mouse study (abstract)
- Population / context
- Mice receiving one of five candidate anti-aging treatments
- Summary based on
- Study abstract
- Publication status
- Preprint · peer-review status not confirmed
- Original publication
- June 16, 2026
8-week screen of five candidate treatments in mice
The abstract describes a short-term performance assay intended to screen longevity interventions in mice quickly, because lifespan studies are slow and costly. Over 8 weeks, mice received one of five candidate anti-aging treatments: 17α-estradiol, rapamycin + Smer28, berberine + resveratrol, sildenafil or pinealon. Body weight, body temperature and food intake were monitored over time. After treatment, grip strength, locomotor activity, Y-maze cognition, social behavior, and hematological and urinary parameters were assessed. The authors present this as a way to profile functional benefits and early toxicity before full lifespan studies.
Supporting source [1]
Compound-specific effects and anemia signal with rapamycin + Smer28
The screen found different patterns for each treatment. 17α-estradiol was associated with significant weight loss, increased grip strength and dorsal alopecia, described as consistent with metabolic remodeling. Sildenafil reduced basal body temperature and preserved locomotor activity. Berberine + resveratrol decreased food intake and fasting glucose without major changes in physical performance, resembling calorie-restriction-like metabolic effects. Rapamycin + Smer28 modestly improved strength and sociability but induced anemia in 2 of 5 mice, indicating potential dose-dependent toxicity. Pinealon showed a trend toward improved working memory without detectable adverse effects. These are short-term observations in mice, not evidence of human benefit.
Supporting source [1]
Abstract-only scope and tokenized funding note
The abstract does not report group sizes beyond the 2 of 5 mice with anemia, nor the duration of post-treatment testing, statistical details or whether the findings persisted. It presents the assay as a screening tool to prioritize and refine doses before full lifespan studies, not as proof that any treatment extends lifespan. The authors also state that, to their knowledge, this is the first comprehensive preclinical aging study in mice fully funded through tokenized decentralized science, describing community-governed, on-chain funding for in vivo research. Only the abstract was available; the full text was not reviewed.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. Group sizes other than 2 of 5 mice, testing duration, statistics and whether effects persisted are not reported. Findings are short-term mouse observations, not evidence of human benefit or lifespan extension.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Marín-Jerez E, Rueda-Carrasco J, Meléndez-Rodríguez F, Partido-Borge P, Tapia E, Leibowitz BD, Parras A. · europepmc.org · June 16, 2026